Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

369

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2029

Conditions

Breast CancerTriple Negative Breast CancerCamrelizumab

Interventions

DRUG

（Carrelizumab + TCb） regimen

Carrelizumab +docetaxel + carboplatin regimen

DRUG

TCb regimen

docetaxel + carboplatin regimen

Trial Locations (1)

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors

lead

Zhenzhen Liu

OTHER_GOV